Heart attack survivors may get Anti-Inflammatory boost from diabetes drug

This study tests whether dapagliflozin, a drug typically used for diabetes, can lower inflammation in the heart arteries of people who recently had a heart attack but do not have diabetes or heart failure. About 110 participants will receive either the drug plus standard care or standard care alone for 6 months. Researchers will use CT scans to measure changes in fat around the arteries, which indicates inflammation levels.